Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OrthocellASX:OCC +3.55%61 Gross Margin % is 54.92% as of Dec. 2025, which is 54% above its 10-year median of 35.59. GuruFocus rates ASX:OCC with a GF Score™ of 61/100 and a GF Value™ of A$1.55 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 734 Biotechnology companies, Orthocell ranks better than 52.18% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Orthocell's Gross Profit for the
six
months ended in Dec. 2025 was A$2.98 Mil. Orthocell's Revenue for the
six
months ended in Dec. 2025 was A$5.42 Mil. Therefore, Orthocell's Gross Margin % for the quarter that ended in Dec. 2025 was 54.92%.
The historical rank and industry rank for Orthocell's Gross Margin % or its related term are showing as below:
ASX:OCC'
s Gross Margin % Range Over the Past 10 Years
Min: 17.36 Med: 35.59 Max: 75.82
Current: 62.71
During the past 12 years, the highestGross Margin % of Orthocell was 75.82%. The lowest was 17.36%. And the median was 35.59%.
ASX:OCC's Gross Margin % is ranked better than 52.18% of 734
companies
in the Biotechnology industry
Industry Median: 60.905
vs ASX:OCC: 62.71
Orthocell had a gross margin of 54.92% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Orthocell was 18.40% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Orthocell had a gross margin of 54.92% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Orthocell Gross Margin % Related Terms
Orthocell Gross Margin % Historical Data
* Premium members only.
The historical data trend for Orthocell's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:OCC vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Orthocell's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orthocell Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Orthocell's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Orthocell's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Orthocell (ASX:OCC) has a Gross Margin % of 54.92% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Orthocell and its competitors. This is 54% above median its historical median of 35.59. Over the past decade, Orthocell's Gross Margin % has ranged from 17.36 to 75.82. According to the industry distribution chart, Orthocell ranks #351 out of 734 companies in the Biotechnology industry, placing it in the top 47.8%.
Is Orthocell's Gross Margin % too high?
Orthocell's current Gross Margin % of 54.92% is 54% above median its 10-year median of 35.59. Over the past 10 years, this metric has ranged from a low of 17.36 to a high of 75.82. The Biotechnology industry median Gross Margin % is 60.91. Orthocell's value of 54.92% is 9.8% below this industry median. Based on the distribution chart, Orthocell ranks #351 out of 734 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Orthocell has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orthocell's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Orthocell ranks #351 out of 734 companies for Gross Margin %. This puts Orthocell in the upper half of its industry. The industry median Gross Margin % is 60.91. Orthocell's value of 54.92% is 9.8% below this benchmark. Historically, Orthocell's own Gross Margin % has ranged from 17.36 to 75.82 over the past decade. While the company's 10-year median is 35.59 vs. the industry median of 60.91, Orthocell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orthocell's current Gross Margin % of 54.92% is 9.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Orthocell and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orthocell's current Gross Margin % is 54.92%, which is 54% above median its own 10-year median of 35.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orthocell stock overvalued right now?
Based on GuruFocus' analysis, Orthocell (ASX:OCC) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.55, compared to a current price of A$0.73 — trading 52.9% below its estimated fair value. The current Gross Margin % is 54.92%, which is 54% above median its 10-year median of 35.59 and 9.8% below the Biotechnology industry median of 60.91. Orthocell's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Orthocell (ASX:OCC), the current Gross Margin % is 54.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orthocell (ASX:OCC) Overvalued in 2026?
Based on GuruFocus' analysis, Orthocell stock appears to be undervalued.
The current stock price of A$0.73 is trading 52.9% below its estimated GF Value™ of A$1.55.
GuruFocus considers Orthocell to be Possible Value Trap.
Key valuation signals for ASX:OCC:
Gross Margin %: 54.92% (54% above median its 10-year median of 35.59)
GF Value™: A$1.55 vs. price of A$0.73 (52.9% below fair value)
Industry Position: 9.8% below the Biotechnology median (#351 of 734)
No single metric tells the full story. See the ASX:OCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir, which is a collagen wrap used in peripheral nerve repair; and OrthoACI, an implant used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline, such as Tendon Cell Therapy and Collagen Medical Device Platform.
61GF Score
Get the complete analysis for ASX:OCC
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OCC has been successfully added to your 
